Johnson & Johnson to present groundbreaking neuropsychiatric research at Psych Congress 2023, featuring advances in depression and schizophrenia treatments
Johnson & Johnson announced that 23 abstracts featuring new real-world and clinical trial data from across its neuropsychiatry portfolio and pipeline will be presented at the annual U.S…. read more.
